Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib

Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.
Latest website image capture
Clouds background image

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page shows a minor version update: Revision: v3.3.4 was added and Revision: v3.3.3 was removed. No observable changes to the study details, layout, or functionality were detected on the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T06:28:54.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The study's Locations section was updated with many new sites across the United States (Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Missouri, New Mexico, New York, Pennsylvania, Texas, Washington), Australia (New South Wales, South Australia, Victoria), Canada (Ontario, Quebec), Italy (Campania, Emilia-Romagna, Piedmont, Sardinia, Tuscany, Veneto), and Russia (Moscow Oblast, Sankt-Peterburg), while several previously listed locations were removed; the revision label updated to v3.3.3 and the HHS Vulnerability Disclosure notice was removed.
    Difference
    1%
    Check dated 2025-12-19T13:59:27.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Page revision shows Revision: v3.3.2 added and Revision: v3.3.1 removed, indicating a minor platform update. This change does not affect the study details, eligibility criteria, outcomes, or navigation on the page.
    Difference
    0.0%
    Check dated 2025-11-28T04:17:34.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Publications section updated to indicate entries are automatically filled from PubMed and to display revision: v3.3.1. The previous PubMed wording and the older revision label v3.2.0 were removed.
    Difference
    0.0%
    Check dated 2025-11-21T02:00:46.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Two new trial locations were added in Tainan, Taiwan (postal codes 00704 and 710). The previous entries listed as 'Tainan City, Taiwan' for those postcodes were removed.
    Difference
    0.2%
    Check dated 2025-11-13T22:33:23.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    Both screenshots show the same study details with no changes to core information such as title, conditions, interventions, eligibility criteria, enrollment numbers, or primary outcomes; only minor formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-30T13:13:03.000Z thumbnail image

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib

Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.